Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prefrontal cortex synaptic density describes the number of synapses present in the prefrontal cortex. Synapses are specialized junctions that enable communication between neurons via electrical and chemical signals. The density of these synapses changes dynamically throughout development, peaking during early childhood and declining during adolescence through a process called synaptic pruning[3]. Regional differences within the cortex are evident, with higher synaptic density observed in associative areas such as the prefrontal cortex, supporting complex cognitive processing, learning, and flexibility[1][3]. Measurement is typically indirect, using markers such as synaptophysin and SV2A via immunohistochemistry or PET imaging[2][5]. Altered synaptic density in the prefrontal cortex is implicated in neuropsychiatric and neurodegenerative diseases and developmental disorders[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prefrontal cortex synaptic density.